Twist Bioscience Corporation (TWST)

NASDAQ: TWST · IEX Real-Time Price · USD
53.91
+0.94 (1.77%)
At close: Aug 15, 2022 4:00 PM
54.17
+0.26 (0.48%)
After-hours: Aug 15, 2022 7:54 PM EDT
1.77%
Market Cap 3.04B
Revenue (ttm) 184.21M
Net Income (ttm) -207.99M
Shares Out 56.36M
EPS (ttm) -3.72
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 722,197
Open 52.18
Previous Close 52.97
Day's Range 51.08 - 54.00
52-Week Range 25.07 - 139.99
Beta 1.18
Analysts Buy
Price Target 49.47 (-8.2%)
Earnings Date Aug 5, 2022

About TWST

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Resea... [Read more...]

Industry Biotechnology
IPO Date Oct 31, 2018
CEO Emily Leproust
Employees 652
Stock Exchange NASDAQ
Ticker Symbol TWST
Full Company Profile

Financial Performance

In 2021, TWST's revenue was $132.33 million, an increase of 46.87% compared to the previous year's $90.10 million. Losses were -$152.10 million, 8.69% more than in 2020.

Financial Statements

Analyst Forecast

According to 15 analysts, the average rating for TWST stock is "Buy." The 12-month stock price forecast is 49.47, which is a decrease of -8.24% from the latest price.

Price Target
$49.47
(-8.24% downside)
Analyst Consensus: Buy
Stock Forecasts

News

Twist Bioscience (TWST) Upgraded to Buy: What Does It Mean for the Stock?

Twist Bioscience (TWST) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Why Twist Bioscience's Shares Rose 25.1% in July

Two bits of positive news spurred the stock's rise.

Twist Bioscience (TWST) Reports Q3 Loss, Tops Revenue Estimates

Twist Bioscience (TWST) delivered earnings and revenue surprises of 16.92% and 9.35%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Twist Bioscience Reports Fiscal Third Quarter 2022 Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon pl...

Twist Bioscience to Present at Flash Memory Summit

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon pl...

Twist Bioscience Highlights White Paper Sizing Future DNA Data Storage Market

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon pl...

Twist Bioscience and Biotia Receive Expanded Emergency Use Authorization to Report Genetic Variants of SARS-CoV-2

SOUTH SAN FRANCISCO, Calif. & NEW YORK--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its...

Twist Bioscience to Present at UBS Genomics 2.0 and Medtech Innovations Summit

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon pl...

Twist Bioscience to Report Fiscal 2022 Third Quarter Financial Results on Friday, August 5, 2022

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon pl...

Twist Bioscience Launches Monkeypox Virus Synthetic DNA Controls For Developing Assays

Twist Bioscience Corp (NASDAQ: TWST) launched two human monkeypox virus synthetic DNA controls. Positive controls provide quality control measures for developing, verifying, and validating both next-gen...

Twist Bioscience Launches Monkeypox Virus Synthetic DNA Controls

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon pl...

DNAnexus and Twist Bioscience Collaborate to Provide Data Analysis Software for NGS Workflow

MOUNTAIN VIEW, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #BiomedicalData--DNAnexus and Twist Bioscience collaboration aims to reduce time to design, validate, and commercialize new, high-q...

7 Best Biotech Stocks to Buy in July 2022

The best biotech stocks to buy are a lot like the best computer stocks 40 years ago; the biggest similarity is how hard they are to predict. The post 7 Best Biotech Stocks to Buy in July 2022 appeared f...

Other symbols: AMGNCRSPEXELIBBIONSMRK

Twist Bioscience Opens New Twist Boston Location to Expand Antibody Discovery Capacity

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon pl...

Twist Bioscience and Ildong Pharmaceutical Enter into a Collaboration to Enhance Antibody Discovery for Applications ...

SOUTH SAN FRANCISCO, Calif. & SEOUL, South Korea--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA...

Twist Bioscience (TWST) Stock Jumps 7.7%: Will It Continue to Soar?

Twist Bioscience (TWST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price incre...

3 Stocks That Could Double by 2025

These companies have realistic prospects of achieving tremendous growth.

Other symbols: AXSMJAZZ

Twist Bioscience to Present at Fujifilm's 12th Annual Global IT Executive Summit

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon pl...

Twist Bioscience Launches Rapid Turnaround, Customizable Panels to Advance R&D in Minimal Residual Disease (MRD) Dete...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #agbt22--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its ...

Twist Bioscience to Present at Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon pl...

Twist Bioscience Launches Human Methylome Panel to Enable Detection of Methylation Fractions in a Diverse Range of Ap...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon pl...

Twist Bioscience to Present at the 2022 UBS Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon pl...

Twist Bioscience Announces Participation in SRC Panel at the 2022 MRS Spring Meeting and Exhibit

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon pl...

Twist Bioscience, Astellas Join Forces To Develop Cancer Targeting Antibodies

Twist Bioscience Corporation (NASDAQ: TWST) has entered into a research collaboration and exclusive option license agreement with Astellas Pharma Inc (OTC: ALPMF) to conduct research activities to ident...

Twist Bioscience Enters into Research, Exclusive Option and License Agreement with Astellas for Antibodies to Reduce ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon pl...